col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

889 Results       Page 1

Springer-Verlag: Reactions Weekly
  original article Date Title Authors   All Authors
1 [GO] 2024―May―11 PPI use increases risk of COVID-19 infections after two doses of COVID-19 vaccine
2 [GO] 2024―May―11 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
3 [GO] 2024―May―03 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
4 [GO] 2024―May―03 COVID-19-vaccine/polymethyl-methacrylate
5 [GO] 2024―May―03 COVID-19-vaccine/prednisone/tacrolimus
6 [GO] 2024―May―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
7 [GO] 2024―May―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/Tozinameran
8 [GO] 2024―Apr―27 COVID-19 vaccine-related heavy menstrual bleeding
9 [GO] 2024―Apr―27 COVID-19-vaccine
10 [GO] 2024―Apr―27 COVID-19-vaccine
11 [GO] 2024―Apr―27 COVID-19-vaccine
12 [GO] 2024―Apr―27 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
13 [GO] 2024―Apr―27 COVID-19-vaccine/Elasomeran
14 [GO] 2024―Apr―27 COVID-19-vaccine/Immune-globulin
15 [GO] 2024―Apr―27 COVID-19-vaccine/Olanzapine
16 [GO] 2024―Apr―27 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
17 [GO] 2024―Apr―27 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
18 [GO] 2024―Apr―12 Moderna COVID-19 vaccine may cause chronic urticaria
19 [GO] 2024―Apr―12 COVID-19 vaccines do not increase GP visits for menstrual disorders
20 [GO] 2024―Apr―12 COVID-19-vaccine
21 [GO] 2024―Apr―12 COVID-19-vaccine
22 [GO] 2024―Apr―12 COVID-19-vaccine/cilgavimab/tixagevimab
23 [GO] 2024―Apr―05 COVID-19-vaccine
24 [GO] 2024―Apr―05 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
25 [GO] 2024―Apr―05 COVID-19-vaccine/nirmatrelvir+ritonavir/tacrolimus
26 [GO] 2024―Apr―05 COVID-19-vaccine/nirmatrelvir+ritonavir/tacrolimus
27 [GO] 2024―Apr―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
28 [GO] 2024―Mar―23 COVID-19 Vaccines
29 [GO] 2024―Mar―23 mRNA COVID-19 vaccines not linked to postmenopausal bleeding
30 [GO] 2024―Mar―23 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/ibuprofen/paracetamol
31 [GO] 2024―Mar―08 Co-administration of bivalent mRNA COVID-19 and influenza vaccines: no new or unexpected safety concerns
32 [GO] 2024―Mar―08 COVID-19-vaccines/Immunosuppressants/Rituximab
33 [GO] 2024―Mar―01 COVID-19 vaccine-related audiovestibular AEs
34 [GO] 2024―Mar―01 COVID-19-vaccine
35 [GO] 2024―Mar―01 COVID-19-vaccine
36 [GO] 2024―Mar―01 COVID-19-vaccines/Prednisone/Valaciclovir
37 [GO] 2024―Feb―22 COVID-19 vaccine
38 [GO] 2024―Feb―22 Risks of neonatal AEs after mRNA COVID-19 vaccine exposure
39 [GO] 2024―Feb―22 Global COVID-19 vaccine study confirms safety signals
40 [GO] 2024―Feb―09 COVID-19-vaccine
41 [GO] 2024―Feb―09 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/thiamazole
42 [GO] 2024―Feb―02 Insufficient evidence to link Long COVID to COVID-19 vaccines
43 [GO] 2024―Feb―02 In utero exposure to COVID-19 vaccines has no neurodevelopmental impact
44 [GO] 2024―Jan―25 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/hydrocortisone
45 [GO] 2024―Jan―13 Differences in rates of AESIs between COVID-19 vaccine types
46 [GO] 2024―Jan―13 COVID-19-vaccine
47 [GO] 2024―Jan―13 COVID-19-vaccine/lamotrigine
48 [GO] 2024―Jan―13 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
49 [GO] 2024―Jan―13 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
50 [GO] 2024―Jan―05 Sudden deafness reported after COVID-19 vaccination
51 [GO] 2024―Jan―05 COVID-19 Vaccines
52 [GO] 2024―Jan―05 COVID-19-vaccine
53 [GO] 2024―Jan―05 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
54 [GO] 2023―Dec―22 No risk of respiratory exacerbation after COVID-19 vaccination
55 [GO] 2023―Dec―14 Corticosteroids/cyclophosphamide/severe acute respiratory syndrome coronavirus 2 mRNA vaccine
56 [GO] 2023―Dec―12 COVID-19 vaccine
57 [GO] 2023―Dec―12 Covid-19-vaccine
58 [GO] 2023―Dec―12 COVID-19-vaccine/tamoxifen
59 [GO] 2023―Dec―12 Sars-cov-2-vaccine-inactivated-sinovac-biotech
60 [GO] 2023―Dec―12 Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran
61 [GO] 2023―Dec―12 Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran
62 [GO] 2023―Dec―04 COVID-19-vaccine
63 [GO] 2023―Dec―04 Covid-19-vaccine/hyaluronic-acid/tozinameran
64 [GO] 2023―Dec―01 COVID-19-vaccine
65 [GO] 2023―Dec―01 Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran
66 [GO] 2023―Nov―25 COVID-19 vaccination: large impact on reporting of ADRs not related to COVID-19 vaccines in France
67 [GO] 2023―Nov―25 mRNA COVID-19 vaccine: side effects more common, recovery prolonged among females and younger adults
68 [GO] 2023―Nov―25 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immune-globulin
69 [GO] 2023―Nov―25 Sars-cov-2-vaccine-inactivated-sinovac-biotech
70 [GO] 2023―Nov―09 COVID-19 vaccine
71 [GO] 2023―Nov―09 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
72 [GO] 2023―Nov―03 Pfizer-BioNTech COVID-19 vaccination safe in adolescents with CKD
73 [GO] 2023―Nov―03 SARS-COV-2 vaccine inactivated Sinovac Biotech
74 [GO] 2023―Nov―03 Sars-cov-2-vaccine-inactivated-sinovac-biotech
75 [GO] 2023―Oct―27 ICMRA statement on safety of COVID-19 vaccines
76 [GO] 2023―Oct―27 COVID-19-vaccine
77 [GO] 2023―Oct―27 Covid-19-vaccine/methotrexate
78 [GO] 2023―Oct―27 COVID-19-vaccines
79 [GO] 2023―Oct―19 COVID-19-vaccine
80 [GO] 2023―Oct―19 Covid-19-vaccine
81 [GO] 2023―Sep―29 Severe acute respiratory syndrome coronavirus-2 mRNA vaccine
82 [GO] 2023―Sep―21 AstraZeneca COVID-19 vaccine-related pityriasis rosea
83 [GO] 2023―Sep―21 AstraZeneca COVID-19 vaccine-related retinal vein occlusion
84 [GO] 2023―Sep―21 SARS-COV-2-vaccine-inactivated
85 [GO] 2023―Sep―18 COVID-19 vaccination does not increase risk of preterm labour
86 [GO] 2023―Sep―18 Safety signal of CIDP with use of AstraZeneca COVID-19 vaccine
87 [GO] 2023―Sep―18 COVID-19-vaccine
88 [GO] 2023―Sep―18 Covid-19-vaccine
89 [GO] 2023―Sep―18 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
90 [GO] 2023―Sep―18 Covid-19-vaccine-pfizer-biontech
91 [GO] 2023―Sep―18 COVID-19-vaccines
92 [GO] 2023―Sep―08 Antibacterial use prior to COVID-19 vaccination increases risk of COVID-19 infection
93 [GO] 2023―Sep―08 Shoulder injury after Pfizer-BioNTech COVID-19 vaccine
94 [GO] 2023―Sep―08 COVID-19 vaccine/nirmatrelvir+ritonavir
95 [GO] 2023―Sep―01 COVID-19 vaccines/immunosuppressants/Varicella zoster virus vaccine
96 [GO] 2023―Sep―01 Sars-cov-2-vaccine-inactivated-sinovac-biotech
97 [GO] 2023―Aug―25 Low risk of urticaria exacerbation following COVID-19 vaccination
98 [GO] 2023―Aug―25 COVID-19 vaccine
99 [GO] 2023―Aug―25 Pfizer-BioNTech COVID-19 vaccine increases risk of myocarditis/pericarditis
100 [GO] 2023―Aug―25 AEs and rheumatic disease flares after COVID-19 vaccine versus influenza vaccine
101 [GO] 2023―Aug―25 Novavax COVID-19 vaccine: no new safety concerns
102 [GO] 2023―Aug―25 COVID-19-vaccine
103 [GO] 2023―Aug―25 COVID-19-vaccine
104 [GO] 2023―Aug―25 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
105 [GO] 2023―Aug―25 COVID-19-Vaccine-Pfizer-BioNTech
106 [GO] 2023―Aug―18 Bivalent mRNA COVID-19 booster vaccines safe in adults
107 [GO] 2023―Aug―18 Co-administered influenza vaccine and mRNA COVID-19 vaccine safe
108 [GO] 2023―Aug―18 COVID-19-vaccine
109 [GO] 2023―Aug―18 COVID-19-vaccines/methylprednisolone
110 [GO] 2023―Aug―18 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
111 [GO] 2023―Aug―11 Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD
112 [GO] 2023―Aug―11 No association between mRNA COVID-19 vaccines and menorrhagia
113 [GO] 2023―Aug―04 Covid-19-vaccine
114 [GO] 2023―Jul―28 Covid-19-vaccine
115 [GO] 2023―Jul―28 COVID-19-vaccine
116 [GO] 2023―Jul―28 COVID-19-vaccines/disease-modifying-antirheumatics interaction
117 [GO] 2023―Jul―28 Severe acute respiratory syndrome coronavirus 2 mrna vaccine
118 [GO] 2023―Jul―21 Societal burden of opioid toxicity-related deaths in the US worsened during COVID-19 pandemic
119 [GO] 2023―Jul―21 Immediate ADRs after COVID-19 vaccination in Denmark
120 [GO] 2023―Jul―21 Novavax COVID-19 vaccine NVX-CoV2373 safe in older adults
121 [GO] 2023―Jul―21 COVID-19 vaccine-related autoimmune haemolytic anaemia
122 [GO] 2023―Jul―21 COVID-19 vaccine-related menstruation disorders
123 [GO] 2023―Jul―21 Covid-19-vaccine/immune-globulin
124 [GO] 2023―Jul―21 Sars-cov-2-vaccine-inactivated-sinovac-biotech
125 [GO] 2023―Jul―14 No major differences in AEs between COVID-19 vaccination schedules
126 [GO] 2023―Jul―14 EMA endorses statement on safety of COVID-19 vaccines issued by ICMRA
127 [GO] 2023―Jul―14 COVID-19-vaccine/dexamethasone/tocilizumab
128 [GO] 2023―Jul―14 SARS-COV-2-vaccine-inactivated-sinovac-biotech/tozinameran
129 [GO] 2023―Jul―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech/zf-2001
130 [GO] 2023―Jul―07 COVID-19 vaccine-related hypersensitivity: basophil reactivity
131 [GO] 2023―Jul―07 EMA publishes report on ensuring safety of COVID-19 vaccines
132 [GO] 2023―Jul―07 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
133 [GO] 2023―Jul―07 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
134 [GO] 2023―Jun―30 COVID-19-vaccine
135 [GO] 2023―Jun―30 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
136 [GO] 2023―Jun―30 Covid-19-vaccine
137 [GO] 2023―Jun―30 Sars-cov-2-vaccine-inactivated-sinovac-biotech
138 [GO] 2023―Jun―23 Covid-19-vaccine/fondaparinux-sodium
139 [GO] 2023―Jun―23 COVID-19 vaccination and cyclophosphamide
140 [GO] 2023―Jun―23 Transverse myelitis after COVID-19 vaccination
141 [GO] 2023―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
142 [GO] 2023―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
143 [GO] 2023―Jun―16 Covid-19-vaccine
144 [GO] 2023―Jun―16 Covid-19-vaccine
145 [GO] 2023―Jun―16 COVID-19 vaccines
146 [GO] 2023―Jun―16 Third mRNA COVID-19 vaccine dose well tolerated in infants and young children
147 [GO] 2023―Jun―16 Sars-cov-2-vaccine-inactivated-sinovac-biotech
148 [GO] 2023―Jun―09 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
149 [GO] 2023―Jun―09 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/dabigatran-etexilate/dipyrone
150 [GO] 2023―Jun―09 Sars-cov-2-vaccine-inactivated-sinovac-biotech
151 [GO] 2023―Jun―02 Covid-19-vaccine
152 [GO] 2023―Jun―02 Covid-19-vaccine
153 [GO] 2023―Jun―02 Covid-19-vaccine
154 [GO] 2023―Jun―02 BNT162b2 COVID-19 vaccine safe in children, signal for myocarditis/pericarditis in adolescents
155 [GO] 2023―May―26 COVID-19-vaccine
156 [GO] 2023―May―18 Covid-19-vaccine/nirmatrelvir+ritonavir/tacrolimus
157 [GO] 2023―May―18 Covid-19-vaccine
158 [GO] 2023―May―18 Nirmatrelvir+ritonavir-related AEs in patients with COVID-19 infections
159 [GO] 2023―May―18 Associations between COVID-19 vaccination and menstruation disorders "weak and inconsistent"
160 [GO] 2023―May―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
161 [GO] 2023―May―18 SARS-COV-2-vaccine-inactivated-sinovac-biotech
162 [GO] 2023―May―12 Covid-19-vaccine
163 [GO] 2023―May―12 Covid-19-vaccine
164 [GO] 2023―May―12 COVID-19-vaccine/dexamethasone
165 [GO] 2023―May―12 Covid-19-vaccine
166 [GO] 2023―May―12 Long-term safety of AstraZeneca COVID-19 vaccine
167 [GO] 2023―May―05 COVID-19-vaccines
168 [GO] 2023―May―05 COVID-19 vaccine-related ADRs in children and adolescents
169 [GO] 2023―May―05 COVID-19 vaccine in adolescents: no new serious safety concerns identified
170 [GO] 2023―May―05 Viral vector-based COVID-19 vaccines: risk of thrombosis with thrombocytopenia
171 [GO] 2023―May―05 Sars-cov-2-vaccine-inactivated-sinovac-biotech
172 [GO] 2023―Apr―28 COVID-19-vaccines
173 [GO] 2023―Apr―28 COVID-19-vaccine/nivolumab
174 [GO] 2023―Apr―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
175 [GO] 2023―Apr―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
176 [GO] 2023―Apr―28 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
177 [GO] 2023―Apr―21 COVID-19-vaccines
178 [GO] 2023―Apr―21 Covid-19-vaccine
179 [GO] 2023―Apr―21 Covid-19 vaccines
180 [GO] 2023―Apr―21 Vulval aphthous ulcers in adolescents after COVID-19 vaccination
181 [GO] 2023―Apr―21 mRNA COVID-19 vaccination not associated with retinal vascular occlusion
182 [GO] 2023―Apr―14 COVID-19-vaccines/glucocorticoids
183 [GO] 2023―Apr―14 Covid-19-vaccine/nirmatrelvir/ritonavir
184 [GO] 2023―Apr―14 COVID-19-vaccine/elasomeran
185 [GO] 2023―Apr―14 Covid-19 vaccine
186 [GO] 2023―Apr―14 COVID-19 vaccination: serious AEs and AESIs rare
187 [GO] 2023―Apr―06 Covid-19-vaccine
188 [GO] 2023―Apr―06 COVID-19 vaccination safety during pregnancy
189 [GO] 2023―Apr―06 Experiences after first COVID-19 vaccination impact severity of AEs after second dose
190 [GO] 2023―Apr―06 SARS-Cov-2-vaccine-inactivated-Sinovac-Biotech
191 [GO] 2023―Apr―06 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
192 [GO] 2023―Mar―31 Covid-19-vaccine
193 [GO] 2023―Mar―31 Covid-19-vaccine
194 [GO] 2023―Mar―31 COVID-19-vaccine
195 [GO] 2023―Mar―31 SARS-COV-2-vaccine-inactivated
196 [GO] 2023―Mar―31 Sars-cov-2-vaccine-inactivated-sinovac-biotech
197 [GO] 2023―Mar―25 Covid-19-vaccine/elasomeran/tozinameran
198 [GO] 2023―Mar―25 Covid-19-vaccine/obinutuzumab
199 [GO] 2023―Mar―25 Covid-19-vaccine-pfizer-biontech
200 [GO] 2023―Mar―25 COVID-19-vaccine
201 [GO] 2023―Mar―25 Covid-19 vaccine
202 [GO] 2023―Mar―23 Covid-19-vaccine
203 [GO] 2023―Mar―23 Covid-19-vaccine
204 [GO] 2023―Mar―23 COVID-19-vaccine
205 [GO] 2023―Mar―23 Covid-19-vaccine
206 [GO] 2023―Mar―23 COVID-19 vaccine-related Guillain-Barre syndrome
207 [GO] 2023―Mar―10 COVID-19 vaccine
208 [GO] 2023―Mar―10 Anxiety and depression increase risk of reporting COVID-19 vaccine-related AEs
209 [GO] 2023―Mar―10 Covid-19-vaccine
210 [GO] 2023―Mar―10 Sars-cov-2 vaccine-inactivated-sinovac-biotech
211 [GO] 2023―Mar―10 SARS-COV-2-vaccine-inactivated-sinovac-biotech
212 [GO] 2023―Mar―03 African countries report fewer AEFIs after COVID-19 vaccination than RoW
213 [GO] 2023―Mar―03 COVID-19 vaccine
214 [GO] 2023―Mar―03 Novavax COVID-19 vaccine-related myocarditis/pericarditis
215 [GO] 2023―Mar―03 HPRA safety update on COVID-19 vaccines up to January 2023
216 [GO] 2023―Mar―03 COVID-19-vaccine
217 [GO] 2023―Mar―03 COVID-19-vaccine/rosuvastatin
218 [GO] 2023―Mar―03 COVID-19-vaccines/fondaparinux-sodium/mannitol
219 [GO] 2023―Mar―03 Sars-cov-2-vaccine-inactivated-sinovac-biotech
220 [GO] 2023―Feb―25 More AEFIs reported after COVID-19 vaccination in females than in males
221 [GO] 2023―Feb―25 COVID-19 vaccine
222 [GO] 2023―Feb―25 Covid-19 vaccine/rituximab
223 [GO] 2023―Feb―25 COVID-19-vaccine
224 [GO] 2023―Feb―25 COVID-19-vaccine
225 [GO] 2023―Feb―25 COVID-19-vaccine
226 [GO] 2023―Feb―25 Covid-19-vaccine
227 [GO] 2023―Feb―25 COVID-19-vaccine
228 [GO] 2023―Feb―25 Covid-19-vaccine
229 [GO] 2023―Feb―25 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
230 [GO] 2023―Feb―25 Covid-19-vaccines
231 [GO] 2023―Feb―25 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
232 [GO] 2023―Feb―25 Sars-cov-2-vaccine-inactivated-sinovac-biotech
233 [GO] 2023―Feb―17 Adverse events following COVID-19 vaccination common but mild in haemodialysis patients
234 [GO] 2023―Feb―17 Covid-19-vaccine
235 [GO] 2023―Feb―17 COVID-19-vaccines
236 [GO] 2023―Feb―11 COVID-19 rebound after use of Paxlovid
237 [GO] 2023―Feb―11 Pregnant women have known AEs after COVID-19 vaccination
238 [GO] 2023―Feb―11 COVID-19 vaccine
239 [GO] 2023―Feb―11 COVID-19 vaccine
240 [GO] 2023―Feb―11 COVID-19 vaccine
241 [GO] 2023―Feb―11 COVID-19 vaccine/rituximab
242 [GO] 2023―Feb―11 Covid-19-vaccine
243 [GO] 2023―Feb―11 COVID-19-vaccine/influenza-virus-vaccine
244 [GO] 2023―Feb―11 Covid-19-vaccine/methylprednisolone
245 [GO] 2023―Feb―11 COVID-19-vaccines/prednisone
246 [GO] 2023―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
247 [GO] 2023―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
248 [GO] 2023―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
249 [GO] 2023―Feb―11 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
250 [GO] 2023―Feb―03 COVID-19-vaccine
251 [GO] 2023―Feb―03 SARS-COV-2-vaccine-inactivated-sinovac-biotech
252 [GO] 2023―Jan―30 Safety of co-administered mRNA COVID-19 and influenza vaccines
253 [GO] 2023―Jan―30 Cilgavimab/tixagevimab unlikely to be active against some COVID-19 Omicron subvariants
254 [GO] 2023―Jan―30 COVID-19 vaccine
255 [GO] 2023―Jan―30 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
256 [GO] 2023―Jan―30 COVID-19-vaccine/nirmatrelvir+ritonavir
257 [GO] 2023―Jan―20 Thyroid dysfunction after COVID-19 vaccination
258 [GO] 2023―Jan―20 COVID-19-vaccine
259 [GO] 2023―Jan―20 COVID-19-vaccine
260 [GO] 2023―Jan―20 COVID-19-vaccines/dexamethasone/tocilizumab
261 [GO] 2023―Jan―20 Sars-cov-2-vaccine inactivated sinovac biotech
262 [GO] 2023―Jan―20 Sars-cov-2-vaccine inactivated sinovac biotech
263 [GO] 2023―Jan―15 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
264 [GO] 2023―Jan―15 Covid-19-vaccine
265 [GO] 2023―Jan―15 Covid-19-vaccine/tozinameran
266 [GO] 2023―Jan―15 No new safety signals after COVID-19 vaccination in New Zealand
267 [GO] 2023―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
268 [GO] 2023―Jan―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
269 [GO] 2023―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
270 [GO] 2023―Jan―14 COVID-19-vaccines
271 [GO] 2023―Jan―14 Covid-19-vaccine-pfizer-biontech/remdesivir
272 [GO] 2023―Jan―14 Covid-19-vaccine/peginterferon-alfa-2a
273 [GO] 2023―Jan―14 COVID-19-vaccine
274 [GO] 2023―Jan―14 COVID-19-vaccine
275 [GO] 2023―Jan―14 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
276 [GO] 2023―Jan―14 COVID-19-vaccine
277 [GO] 2023―Jan―14 Covid-19-vaccine
278 [GO] 2023―Jan―14 Covid-19-vaccine
279 [GO] 2023―Jan―14 Covid-19-vaccine
280 [GO] 2023―Jan―14 Covid-19-vaccine
281 [GO] 2023―Jan―14 COVID-19 vaccines
282 [GO] 2023―Jan―14 POTS less frequent after COVID-19 vaccine than after COVID infection
283 [GO] 2023―Jan―14 COVID-19 vaccine
284 [GO] 2022―Dec―16 ADRs following use of oral COVID-19 therapeutics (Paxlovid, Lagevrio) in New Zealand
285 [GO] 2022―Dec―16 Covid-19-vaccine
286 [GO] 2022―Dec―16 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
287 [GO] 2022―Dec―16 Sars-cov-2-vaccine-inactivated
288 [GO] 2022―Dec―10 FDA drug safety surveillance during COVID-19 pandemic
289 [GO] 2022―Dec―10 COVID-19 vaccine
290 [GO] 2022―Dec―10 Safety of second Pfizer-BioNTech COVID-19 vaccine booster
291 [GO] 2022―Dec―10 Covid-19-vaccine
292 [GO] 2022―Dec―10 Covid-19-vaccine
293 [GO] 2022―Dec―10 Covid-19-vaccine
294 [GO] 2022―Dec―10 Covid-19-vaccine
295 [GO] 2022―Dec―10 COVID-19-vaccine/nivolumab/pembrolizumab
296 [GO] 2022―Dec―10 Covid-19-vaccine/ocrelizumab
297 [GO] 2022―Dec―10 SARS-COV-2-vaccine-inactivated-sinovac-biotech
298 [GO] 2022―Dec―10 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
299 [GO] 2022―Dec―02 COVID-19 vaccines safe in patients with systemic lupus erythematosus
300 [GO] 2022―Dec―02 COVID-19-vaccine
301 [GO] 2022―Dec―02 Covid-19-vaccine
302 [GO] 2022―Dec―02 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
303 [GO] 2022―Dec―02 Covid-19-vaccine/elasomeran/tozinameran
304 [GO] 2022―Dec―02 COVID-19-vaccines/immunosuppressants/tocilizumab
305 [GO] 2022―Nov―28 Severe AEs after COVID-19 vaccination following COVID-19 infection
306 [GO] 2022―Nov―28 Dedicated system for COVID-19 vaccine safety surveillance at Lareb
307 [GO] 2022―Nov―28 COVID-19 vaccine-associated Guillain-Barre syndrome
308 [GO] 2022―Nov―28 COVID-19-vaccine
309 [GO] 2022―Nov―28 Covid-19-vaccine
310 [GO] 2022―Nov―28 COVID-19-vaccines
311 [GO] 2022―Nov―28 COVID-19-vaccines/prednisone
312 [GO] 2022―Nov―28 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
313 [GO] 2022―Nov―19 COVID-19 vaccine-related neuralgic amyotrophy
314 [GO] 2022―Nov―19 Pfizer-BioNTech and Moderna COVID-19 vaccines safe in Japan
315 [GO] 2022―Nov―19 COVID-19-vaccine
316 [GO] 2022―Nov―19 Covid-19-vaccine
317 [GO] 2022―Nov―19 COVID-19-vaccine/propylthiouracil
318 [GO] 2022―Nov―11 Pfizer-BioNTech COVID-19 vaccination in children: no serious AEs
319 [GO] 2022―Nov―11 Covid-19-vaccine
320 [GO] 2022―Nov―11 Covid-19-vaccine
321 [GO] 2022―Nov―11 COVID-19-vaccine
322 [GO] 2022―Nov―11 Covid-19-vaccine
323 [GO] 2022―Nov―11 Covid-19-vaccine
324 [GO] 2022―Nov―11 COVID-19-vaccines
325 [GO] 2022―Nov―07 Risks of thrombosis and thromboembolic events after first COVID-19 vaccination
326 [GO] 2022―Nov―07 No pregnancy complications after use of mRNA COVID-19 vaccines
327 [GO] 2022―Nov―07 Covid-19-vaccine
328 [GO] 2022―Nov―07 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
329 [GO] 2022―Nov―07 COVID-19-vaccines/immune-globulin/methylprednisolone
330 [GO] 2022―Oct―28 AEs in children after Pfizer-BioNTech COVID-19 vaccine
331 [GO] 2022―Oct―28 Safety of BNT162b2 COVID-19 vaccine comparable to that of other approved vaccines in young children
332 [GO] 2022―Oct―28 Risk of COVID-19 vaccine-related tinnitus
333 [GO] 2022―Oct―28 Covid-19-vaccine
334 [GO] 2022―Oct―28 Covid-19-vaccine
335 [GO] 2022―Oct―28 COVID-19-vaccine/immune-globulin/methylprednisolone
336 [GO] 2022―Oct―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
337 [GO] 2022―Oct―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
338 [GO] 2022―Oct―21 Multiple sclerosis immunotherapies increase risk of COVID-19 mortality
339 [GO] 2022―Oct―21 AEs after COVID-19 vaccination in patients with epilepsy
340 [GO] 2022―Oct―21 COVID-19 vaccine-related anaphylaxis and other allergic reactions
341 [GO] 2022―Oct―21 COVID-19-vaccine
342 [GO] 2022―Oct―21 Covid-19-vaccine
343 [GO] 2022―Oct―21 Covid-19-vaccine
344 [GO] 2022―Oct―21 Covid-19-vaccine
345 [GO] 2022―Oct―21 Covid-19-vaccine
346 [GO] 2022―Oct―21 Covid-19-vaccine
347 [GO] 2022―Oct―21 COVID-19-vaccine-pfizer-biontech/lisinopril/metoprolol
348 [GO] 2022―Oct―21 COVID-19-vaccine/temozolomide
349 [GO] 2022―Oct―21 COVID-19-vaccines
350 [GO] 2022―Oct―21 COVID-19-vaccines
351 [GO] 2022―Oct―14 mRNA COVID-19 vaccine safety in recipients aged 12 to 64 years
352 [GO] 2022―Oct―14 Covid-19-vaccine
353 [GO] 2022―Oct―14 COVID-19-vaccine
354 [GO] 2022―Oct―14 Covid-19-vaccine/elasomeran/tozinameran
355 [GO] 2022―Oct―14 Covid-19-vaccine/olanzapine
356 [GO] 2022―Oct―14 SARS-COV-2 vaccine inactivated Sinovac Biotech
357 [GO] 2022―Oct―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
358 [GO] 2022―Oct―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
359 [GO] 2022―Oct―07 COVID-19 vaccination may trigger tattoo skin reactions
360 [GO] 2022―Oct―07 Coronavirus-vaccine
361 [GO] 2022―Oct―07 Coronavirus-vaccine-stemirna-therapeutics/tongji-university/tozinameran
362 [GO] 2022―Oct―07 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
363 [GO] 2022―Oct―01 Headache common after COVID-19 vaccination
364 [GO] 2022―Oct―01 COVID-19 vaccine
365 [GO] 2022―Oct―01 Sars-cov-2-vaccine-inactivated-sinovac-biotech
366 [GO] 2022―Sep―23 Myocardial injury after 4th dose of Pfizer-BioNTech COVID-19 vaccine
367 [GO] 2022―Sep―23 Novavax COVID-19 vaccine-related myocarditis and pericarditis
368 [GO] 2022―Sep―23 Side effects common after first dose of COVID-19 vaccine: a survey from Spain
369 [GO] 2022―Sep―23 COVID-19-vaccine
370 [GO] 2022―Sep―23 COVID-19-vaccine
371 [GO] 2022―Sep―23 Covid-19-vaccine
372 [GO] 2022―Sep―23 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
373 [GO] 2022―Sep―23 Covid-19-vaccine/methotrexate/tumour-necrosis-factor-inhibitors
374 [GO] 2022―Sep―23 COVID-19-vaccines/prednisolone/rituximab
375 [GO] 2022―Sep―16 COVID-19 outcome not worsened by remdesivir-induced bradycardia
376 [GO] 2022―Sep―16 Serious AEs of special interest after mRNA COVID-19 vaccination
377 [GO] 2022―Sep―16 COVID-19 vaccine
378 [GO] 2022―Sep―16 Sars-cov-2-vaccine-inactivated-sinovac-biotech
379 [GO] 2022―Sep―16 Sars-cov-2-vaccine-inactivated-sinovac-biotech
380 [GO] 2022―Sep―09 TTS rare after AstraZeneca COVID-19 vaccine
381 [GO] 2022―Sep―09 Safety profile of BBV152 COVID-19 vaccine favourable in adolescents in India
382 [GO] 2022―Sep―09 Covid-19-vaccine
383 [GO] 2022―Sep―09 Covid-19-vaccine/elasomeran
384 [GO] 2022―Sep―02 COVID-19 vaccination safe during pregnancy
385 [GO] 2022―Sep―02 COVID-19 vaccine
386 [GO] 2022―Sep―02 AstraZeneca, Pfizer-BioNTech, Sinopharm, Sputnik V COVID-19 vaccine
387 [GO] 2022―Sep―02 Covid-19 vaccine Gamaleya national research center of epidemiology and microbiology/fenoterol/ipratropium bromide
388 [GO] 2022―Sep―02 Adenoviral-based COVID-19 vaccines may increase risk of MI and PE
389 [GO] 2022―Sep―02 COVID-19-vaccine
390 [GO] 2022―Sep―02 COVID-19-vaccine
391 [GO] 2022―Sep―02 COVID-19-Vaccine-Pfizer-BioNTech
392 [GO] 2022―Sep―02 SARS-COV-2 vaccine-inactivated Sinovac-Biotech
393 [GO] 2022―Sep―02 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
394 [GO] 2022―Aug―26 COVID-19 mRNA vaccines safe in pregnancy
395 [GO] 2022―Aug―26 COVID-19 vaccination hesitancy may drive AE reporting
396 [GO] 2022―Aug―26 Novavax COVID-19 vaccine-related myocarditis, pericarditis
397 [GO] 2022―Aug―26 Covid-19-vaccine
398 [GO] 2022―Aug―26 COVID-19-vaccine/dexamethasone/tobramycin
399 [GO] 2022―Aug―19 Cutaneous reactions after COVID-19 vaccination
400 [GO] 2022―Aug―19 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
401 [GO] 2022―Aug―19 COVID-19-vaccines/immune globulin
402 [GO] 2022―Aug―12 Serious AEs uncommon after second mRNA COVID-19 booster
403 [GO] 2022―Aug―12 AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia case fatalities
404 [GO] 2022―Aug―12 COVID-19 vaccines: risk of oral adverse events
405 [GO] 2022―Aug―12 Covid-19-vaccine
406 [GO] 2022―Aug―12 Sars-cov-2-vaccine-inactivated-sinovac-biotech
407 [GO] 2022―Aug―12 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
408 [GO] 2022―Aug―06 Covid-19 vaccine
409 [GO] 2022―Aug―06 COVID-19-vaccine
410 [GO] 2022―Jul―29 Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons
411 [GO] 2022―Jul―29 COVID-19 vaccination: reports of Bell's palsy
412 [GO] 2022―Jul―29 COVID-19 vaccine
413 [GO] 2022―Jul―29 COVID-19 vaccine: risk of increased menstrual bleeding
414 [GO] 2022―Jul―29 COVID-19-vaccine
415 [GO] 2022―Jul―29 COVID-19-vaccine/ipilimumab/nivolumab
416 [GO] 2022―Jul―29 COVID-19-vaccines
417 [GO] 2022―Jul―23 Covid-19-vaccine
418 [GO] 2022―Jul―23 COVID-19-vaccine
419 [GO] 2022―Jul―23 Sars-cov-2 vaccine inactivated Sinovac Biotech/tozinameran
420 [GO] 2022―Jul―15 Covid-19 vaccine
421 [GO] 2022―Jul―15 Active surveillance confirms short-term safety of COVID-19 vaccines in Australia
422 [GO] 2022―Jul―15 COVID-19 vaccines: reports of lichen planus
423 [GO] 2022―Jul―15 Covid-19-vaccine
424 [GO] 2022―Jul―15 Covid-19-vaccine
425 [GO] 2022―Jul―15 Covid-19-vaccine
426 [GO] 2022―Jul―15 COVID-19-vaccine
427 [GO] 2022―Jul―15 Covid-19-vaccine-pfizer-biontech/elasomeran
428 [GO] 2022―Jul―15 Sars-cov-2-vaccine-inactivated-sinovac-biotech
429 [GO] 2022―Jul―08 Myocarditis/pericarditis rare after COVID-19 mRNA vaccination
430 [GO] 2022―Jul―08 Covid-19 vaccine pfizer biontech
431 [GO] 2022―Jul―08 Covid-19 vaccine pfizer biontech
432 [GO] 2022―Jul―08 Covid-19-vaccine
433 [GO] 2022―Jul―08 Covid-19-vaccine
434 [GO] 2022―Jul―08 COVID-19-vaccine
435 [GO] 2022―Jul―08 SARS-COV-2-vaccine inactivated Sinovac Biotech
436 [GO] 2022―Jul―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech
437 [GO] 2022―Jul―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran
438 [GO] 2022―Jul―01 Covid-19 vaccine
439 [GO] 2022―Jul―01 COVID-19 vaccine Pfizer BioNTech
440 [GO] 2022―Jul―01 Signal detection of COVID-19 vaccine-related AEs
441 [GO] 2022―Jul―01 COVID-19-vaccine
442 [GO] 2022―Jul―01 COVID-19-Vaccine-Pfizer-BioNTech
443 [GO] 2022―Jul―01 Covid-19-vaccine-Pfizer-BioNTech
444 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech
445 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech
446 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech
447 [GO] 2022―Jul―01 COVID-19-vaccine-Pfizer-Biontech/elasomeran
448 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech/olanzapine/tetrabenazine
449 [GO] 2022―Jul―01 COVID-19-vaccines/immunosuppressants
450 [GO] 2022―Jul―01 SARS-CoV-2 vaccine inactivated Sinovac Biotech
451 [GO] 2022―Jul―01 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
452 [GO] 2022―Jun―23 Acute neurological AEs after COVID-19 vaccination
453 [GO] 2022―Jun―23 COVID-19 vaccination and risk of neuralgic amyotrophy
454 [GO] 2022―Jun―23 COVID-19 vaccination relatively safe in autoimmune diseases
455 [GO] 2022―Jun―23 COVID-19 vaccines/mycophenolate mofetil
456 [GO] 2022―Jun―23 Sars-cov-2-vaccine-inactivated
457 [GO] 2022―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
458 [GO] 2022―Jun―23 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
459 [GO] 2022―Jun―23 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
460 [GO] 2022―Jun―17 Risk of myocarditis or pericarditis after COVID-19 mRNA vaccines
461 [GO] 2022―Jun―17 Risk of Guillain-Barre Syndrome after COVID-19 vaccination
462 [GO] 2022―Jun―17 Janssen COVID-19 vaccine increases risk of thrombocytopenia
463 [GO] 2022―Jun―17 COVID-19 vaccine-Pfizer-BioNTech
464 [GO] 2022―Jun―17 Covid-19-vaccine first report
465 [GO] 2022―Jun―17 Covid-19-vaccine-pfizer-biontech
466 [GO] 2022―Jun―17 SARS-COV-2-vaccine-inactivated Sinovac-Biotech
467 [GO] 2022―Jun―17 Sars-cov-2-vaccine-inactivated-sinovac-biotech
468 [GO] 2022―Jun―17 Sars-cov-2-vaccine-inactivated-sinovac-biotech
469 [GO] 2022―Jun―10 AEs after homologous versus heterologous COVID-19 booster
470 [GO] 2022―Jun―10 Standardised assessment of COVID-19 vaccine-related skin reactions
471 [GO] 2022―Jun―10 Safety of mRNA COVID-19 vaccines during pregnancy
472 [GO] 2022―Jun―10 Covid-19-vaccine/lamotrigine
473 [GO] 2022―Jun―03 Low risk of myopericarditis after COVID-19 vaccination in children aged 5-11 years
474 [GO] 2022―Jun―03 Pfizer-BioNTech COVID-19 vaccine safe with clozapine
475 [GO] 2022―Jun―03 COVID-19 vaccine-induced VITT/TSS in Malaysia
476 [GO] 2022―Jun―03 Lareb study on COVID-19 vaccine-related menstrual disorders
477 [GO] 2022―Jun―03 COVID-19-vaccine
478 [GO] 2022―Jun―03 COVID-19-vaccine
479 [GO] 2022―Jun―03 COVID-19-Vaccine-Pfizer-BioNTech
480 [GO] 2022―Jun―03 Covid-19-vaccine-pfizer-biontech
481 [GO] 2022―Jun―03 COVID-19-vaccine-Pfizer-BioNtech
482 [GO] 2022―Jun―03 COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
483 [GO] 2022―Jun―03 Sars-cov-2-vaccine-inactivated-sinovac-biotech
484 [GO] 2022―Jun―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
485 [GO] 2022―Jun―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
486 [GO] 2022―May―27 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
487 [GO] 2022―May―27 Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
488 [GO] 2022―May―27 Pfizer-BioNTech COVID-19 vaccine safe in children
489 [GO] 2022―May―27 Covid-19-vaccine
490 [GO] 2022―May―27 Covid-19-vaccine
491 [GO] 2022―May―27 Covid-19-vaccine
492 [GO] 2022―May―27 Covid-19-vaccine-pfizer-biontech
493 [GO] 2022―May―27 Covid-19-vaccine-pfizer-biontech/elasomeran
494 [GO] 2022―May―20 ADRs due to off-label use of hydroxychloroquine for COVID-19
495 [GO] 2022―May―20 Survey of adverse events following ChAdOx1 COVID-19 vaccination in Ethiopia
496 [GO] 2022―May―20 COVID-19-vaccine
497 [GO] 2022―May―20 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immunosuppressants
498 [GO] 2022―May―20 COVID-19-Vaccine-Pfizer-BioNTech
499 [GO] 2022―May―20 Covid-19-vaccine-pfizer-biontech
500 [GO] 2022―May―20 Covid-19-vaccine-pfizer-biontech/levothyroxine-sodium/sars-cov-2-vaccine-inactivated-sinovac-biotech
501 [GO] 2022―May―20 COVID-19-vaccines/budesonide/mesalazine
502 [GO] 2022―May―13 FDA limits authorised use of Janssen COVID-19 vaccine
503 [GO] 2022―May―13 Covid-19-vaccine-pfizer-biontech
504 [GO] 2022―May―13 COVID-19-Vaccine-Pfizer-BioNTech
505 [GO] 2022―May―13 Covid-19-vaccine-pfizer-biontech
506 [GO] 2022―May―13 COVID-19-vaccine/plasma
507 [GO] 2022―May―13 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
508 [GO] 2022―May―06 COVID-19 vaccination may reactivate varicella-zoster virus
509 [GO] 2022―May―06 COVID-19-Vaccine-Pfizer-BioNTech
510 [GO] 2022―May―06 COVID-19-Vaccine-Pfizer-BioNTech
511 [GO] 2022―Apr―29 No increased risk for venous thromboembolism after COVID-19 vaccination
512 [GO] 2022―Apr―29 Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
513 [GO] 2022―Apr―29 COVID-19 vaccine Gamaleya National Research Center of Epidemiology and Microbiology
514 [GO] 2022―Apr―29 COVID-19 Vaccine Pfizer BioNTech
515 [GO] 2022―Apr―29 Covid-19-vaccine
516 [GO] 2022―Apr―29 COVID-19-Vaccine-Pfizer-BioNTech/pegfilgrastim/pembrolizumab
517 [GO] 2022―Apr―29 Covid-19-vaccine/methylprednisolone
518 [GO] 2022―Apr―29 COVID-19-vaccine/mycophenolate
519 [GO] 2022―Apr―22 Cardiac risks higher after COVID-19 infection than mRNA vaccine
520 [GO] 2022―Apr―22 Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
521 [GO] 2022―Apr―22 PRAC meeting highlights April 2022: no link between mRNA COVID-19 vaccines and autoimmune hepatitis
522 [GO] 2022―Apr―22 Covid-19-vaccine
523 [GO] 2022―Apr―22 Covid-19-vaccine-pfizer-biontech
524 [GO] 2022―Apr―22 COVID-19-Vaccine-Pfizer-BioNTech
525 [GO] 2022―Apr―22 COVID-19-Vaccine-Pfizer-BioNTech/elasomeran
526 [GO] 2022―Apr―22 Covid-19-vaccine-pfizer-biontech/prednisone/valaciclovir
527 [GO] 2022―Apr―22 COVID-19-vaccines/immune-globulin/methylprednisolone
528 [GO] 2022―Apr―22 Coronavirus-vaccine
529 [GO] 2022―Apr―14 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
530 [GO] 2022―Apr―14 Covid-19-vaccine-pfizer-biontech
531 [GO] 2022―Apr―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
532 [GO] 2022―Apr―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
533 [GO] 2022―Apr―08 Remdesivir does not increase risk of AKI or ALI in COVID-19 patients
534 [GO] 2022―Apr―08 COVID-19 vaccine-Pfizer-BioNTech/methylprednisolone aceponate
535 [GO] 2022―Apr―08 No evidence of adverse neurological outcomes from COVID-19 vaccines
536 [GO] 2022―Apr―08 Covid-19-vaccine
537 [GO] 2022―Apr―08 COVID-19-vaccine
538 [GO] 2022―Apr―08 Covid-19-vaccine
539 [GO] 2022―Apr―08 Covid-19-vaccine-pfizer-biontech
540 [GO] 2022―Apr―08 Covid-19-vaccine-pfizer-biontech
541 [GO] 2022―Apr―08 COVID-19-Vaccine-Pfizer-BioNTech
542 [GO] 2022―Apr―08 COVID-19-Vaccine-Pfizer-BioNTech
543 [GO] 2022―Apr―08 Covid-19-vaccine/evolocumab
544 [GO] 2022―Apr―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech
545 [GO] 2022―Apr―08 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
546 [GO] 2022―Apr―01 No safety signal after COVID-19 vaccination for immune-mediated neurological events
547 [GO] 2022―Apr―01 Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine
548 [GO] 2022―Apr―01 COVID-19-vaccine
549 [GO] 2022―Apr―01 Covid-19-vaccine
550 [GO] 2022―Apr―01 COVID-19-Vaccine-Pfizer-BioNTech
551 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech
552 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech
553 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech/ibuprofen/paracetamol/meloxicam
554 [GO] 2022―Apr―01 Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
555 [GO] 2022―Mar―25 Systemic AEs common after COVID-19 vaccination
556 [GO] 2022―Mar―25 COVID-19 vaccine Gamaleya National Research Center of Epidermiology and Microbiology
557 [GO] 2022―Mar―25 Covid-19 vaccine-Pfizer-BioNtech
558 [GO] 2022―Mar―25 Covid-19-vaccine
559 [GO] 2022―Mar―25 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/fexofenadine
560 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech
561 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech
562 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech/sars-cov-2-vaccine-inactivated-sinovac-biotech
563 [GO] 2022―Mar―25 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
564 [GO] 2022―Mar―19 Covid-19-vaccine-pfizer-biontech
565 [GO] 2022―Mar―19 COVID-19-Vaccine-Pfizer-BioNTech/elasomeran
566 [GO] 2022―Mar―19 Sars-cov-2-vaccine-inactivated-sinovac-biotech
567 [GO] 2022―Mar―19 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
568 [GO] 2022―Mar―19 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
569 [GO] 2022―Mar―11 Covid-19-vaccine-pfizer-biontech
570 [GO] 2022―Mar―11 Covid-19-vaccine-pfizer-biontech/elasomeran
571 [GO] 2022―Mar―11 Coronavirus-vaccine
572 [GO] 2022―Mar―11 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
573 [GO] 2022―Mar―05 Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits
574 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
575 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
576 [GO] 2022―Mar―05 COVID-19-vaccine-pfizer-biontech
577 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
578 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
579 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech
580 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
581 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech
582 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech/omalizumab
583 [GO] 2022―Mar―05 Covid-19-vaccine/vildagliptin interaction
584 [GO] 2022―Mar―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
585 [GO] 2022―Feb―25 COVID-19 vaccine
586 [GO] 2022―Feb―25 COVID-19 vaccine
587 [GO] 2022―Feb―25 COVID-19 vaccine
588 [GO] 2022―Feb―25 Covid-19-vaccine
589 [GO] 2022―Feb―25 Covid-19-vaccine-pfizer-biontech
590 [GO] 2022―Feb―25 Covid-19-vaccine-pfizer-biontech
591 [GO] 2022―Feb―25 COVID-19-Vaccine-Pfizer-BioNTech/epinephrine
592 [GO] 2022―Feb―18 Increase in thromboembolic ADRs from oral contraceptives during COVID-19 pandemic in Spain
593 [GO] 2022―Feb―18 No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine
594 [GO] 2022―Feb―18 COVID-19 Vaccine Pfizer BioNTech
595 [GO] 2022―Feb―18 COVID-19 Vaccine Pfizer BioNTech
596 [GO] 2022―Feb―18 COVID-19-Vaccine-Pfizer-BioNTech
597 [GO] 2022―Feb―18 COVID-19-Vaccine-Pfizer-BioNTech
598 [GO] 2022―Feb―18 Coronavirus-vaccine
599 [GO] 2022―Feb―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
600 [GO] 2022―Feb―11 mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections
601 [GO] 2022―Feb―11 COVID-19 vaccine errors dominate ISMP's list of top 10 safety concerns for 2021
602 [GO] 2022―Feb―11 Covid-19-vaccine-pfizer-biontech
603 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
604 [GO] 2022―Feb―11 Covid-19-vaccine-pfizer-biontech
605 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
606 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
607 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
608 [GO] 2022―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
609 [GO] 2022―Feb―04 Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
610 [GO] 2022―Feb―04 COVID-19 vaccine
611 [GO] 2022―Feb―04 Growing evidence reassuring for mRNA COVID-19 vaccines in pregnancy
612 [GO] 2022―Feb―04 COVID-19-vaccine
613 [GO] 2022―Feb―04 Covid-19-vaccine
614 [GO] 2022―Feb―04 Covid-19-vaccine
615 [GO] 2022―Jan―28 Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs
616 [GO] 2022―Jan―28 Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event
617 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
618 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
619 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
620 [GO] 2022―Jan―28 COVID-19-Vaccine-Pfizer-BioNTech
621 [GO] 2022―Jan―28 COVID-19-Vaccine-Pfizer-BioNTech
622 [GO] 2022―Jan―28 Coronavirus-vaccine
623 [GO] 2022―Jan―28 Coronavirus-vaccine
624 [GO] 2022―Jan―21 COVID-19 vaccines safe in people living with HIV
625 [GO] 2022―Jan―21 SARS-COV-2 vaccine inactivated Sinovac Biotech
626 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
627 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
628 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
629 [GO] 2022―Jan―14 Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
630 [GO] 2022―Jan―14 Rare reports of rheumatic disorder flares after COVID-19 vaccination
631 [GO] 2022―Jan―14 Small change in menstrual cycle length after COVID-19 vaccination
632 [GO] 2022―Jan―14 Expected rates of adverse events after COVID-19 vaccination in USA
633 [GO] 2022―Jan―14 Covid-19-vaccine/tozinameran
634 [GO] 2022―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
635 [GO] 2022―Jan―06 Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
636 [GO] 2022―Jan―06 COVID-19 Vaccine Pfizer BioNTech
637 [GO] 2022―Jan―06 Signal for COVID-19 vaccine-related menstrual disorders
638 [GO] 2022―Jan―06 Systematic review: COVID-19 vaccine-related neurological disorders "exceedingly" rare
639 [GO] 2022―Jan―06 COVID-19-vaccine
640 [GO] 2022―Jan―06 COVID-19-vaccine
641 [GO] 2022―Jan―06 COVID-19-vaccine
642 [GO] 2022―Jan―06 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
643 [GO] 2022―Jan―06 COVID-19-Vaccine-Pfizer-BioNTech
644 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
645 [GO] 2022―Jan―06 COVID-19-Vaccine-Pfizer-BioNTech
646 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
647 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
648 [GO] 2022―Jan―06 Covid-19-vaccine/influenza-virus-vaccine
649 [GO] 2022―Jan―06 Covid-19-vaccine/mrna-1273
650 [GO] 2022―Jan―06 SARS-COV-2 vaccine inactivated-Sinovac-Biotech
651 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
652 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
653 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
654 [GO] 2021―Dec―18 COVID-19 Vaccine Pfizer-BioNTech
655 [GO] 2021―Dec―18 Most adolescent myocarditis cases related to covid-19 vaccines mild, resolve quickly
656 [GO] 2021―Dec―18 Covid-19-vaccine-pfizer-biontech
657 [GO] 2021―Dec―18 COVID-19-Vaccine-Pfizer-BioNTech
658 [GO] 2021―Dec―18 Coronavirus vaccine
659 [GO] 2021―Dec―18 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
660 [GO] 2021―Dec―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
661 [GO] 2021―Dec―10 Safety of seven COVID-19 vaccine booster doses
662 [GO] 2021―Dec―10 Myocarditis, pericarditis with COVID-19 vaccines in the Netherlands
663 [GO] 2021―Dec―10 COVID-19 vaccines/rituximab
664 [GO] 2021―Dec―10 COVID-19-Vaccine-Pfizer-BioNTech
665 [GO] 2021―Dec―10 COVID-19-Vaccine-Pfizer-BioNTech
666 [GO] 2021―Dec―10 Covid-19-vaccine/immune-globulin/methylprednisolone
667 [GO] 2021―Dec―10 COVID-19-vaccines
668 [GO] 2021―Dec―10 Covid-19-vaccines/rituximab
669 [GO] 2021―Dec―10 Sars-cov-2-vaccine-inactivated-sinovac-biotech
670 [GO] 2021―Dec―10 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
671 [GO] 2021―Dec―04 Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
672 [GO] 2021―Dec―04 No increase in stroke, MI or PE after Pfizer-BioNTech COVID-19 vaccine
673 [GO] 2021―Dec―04 Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador
674 [GO] 2021―Dec―04 Pfizer-BioNTech COVID-19 vaccine safe in older Koreans
675 [GO] 2021―Dec―04 COVID-19-vaccine
676 [GO] 2021―Dec―04 COVID-19-Vaccine-Pfizer-BioNTech
677 [GO] 2021―Dec―04 Covid-19-vaccine-pfizer-biontech
678 [GO] 2021―Dec―04 Covid-19-vaccine-pfizer-biontech
679 [GO] 2021―Dec―04 COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273
680 [GO] 2021―Dec―04 Coronavirus-vaccine
681 [GO] 2021―Dec―04 Coronavirus-vaccine-Wuhan-Institute-of-Biological-Products
682 [GO] 2021―Nov―26 Cutaneous vasculitis following COVID-19 vaccination
683 [GO] 2021―Nov―26 COVID-19 vaccine Pfizer BioNTech
684 [GO] 2021―Nov―26 Possibility of mix-up with paediatric COVID-19 vaccines
685 [GO] 2021―Nov―26 COVID-19-Vaccine-Pfizer-BioNTech
686 [GO] 2021―Nov―26 Covid-19-vaccine-pfizer-biontech
687 [GO] 2021―Nov―26 Covid-19-vaccine-pfizer-biontech
688 [GO] 2021―Nov―19 Myocarditis rare after COVID-19 mRNA vaccination
689 [GO] 2021―Nov―19 Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine
690 [GO] 2021―Nov―19 English-only labels for Janssen's COVID-19 vaccine in Canada
691 [GO] 2021―Nov―19 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
692 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
693 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
694 [GO] 2021―Nov―19 COVID-19-Vaccine-Pfizer-BioNTech
695 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
696 [GO] 2021―Nov―19 COVID-19-vaccine-pfizer-biontech/ibuprofen/oxycodone
697 [GO] 2021―Nov―19 Covid-19-vaccine-Pfizer-BioNTech/mRNA-1273
698 [GO] 2021―Nov―05 COVID-19 vaccine
699 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
700 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
701 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
702 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
703 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
704 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
705 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273
706 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech/mycophenolic acid/tacrolimus
707 [GO] 2021―Nov―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
708 [GO] 2021―Oct―29 Covid-19-vaccine-pfizer-biontech
709 [GO] 2021―Oct―29 COVID-19-Vaccine-Pfizer-BioNTech
710 [GO] 2021―Oct―29 Covid-19-vaccine/rituximab
711 [GO] 2021―Oct―22 COVID-19-Vaccine-Pfizer-BioNTech
712 [GO] 2021―Oct―22 Covid-19-vaccine-pfizer-biontech
713 [GO] 2021―Oct―22 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
714 [GO] 2021―Oct―16 Pfizer-BioNTech COVID-19 vaccine in patients with severe allergies
715 [GO] 2021―Oct―16 Covid-19-vaccine
716 [GO] 2021―Oct―16 COVID-19-vaccine
717 [GO] 2021―Oct―16 COVID-19-Vaccine-Pfizer-BioNTech
718 [GO] 2021―Oct―16 SARS-COV-2 vaccine inactivated Sinovac Biotech
719 [GO] 2021―Oct―16 No evidence of birth defects or spontaneous abortion from pandemic H1N1-influenza vaccine
720 [GO] 2021―Oct―10 Covid-19 vaccine-Pfizer-Biontech
721 [GO] 2021―Oct―10 No association between COVID-19 vaccination and menstrual disorders
722 [GO] 2021―Oct―01 FAPIC score predicts mortality after COVID-19 vaccine-related TTS
723 [GO] 2021―Oct―01 Product monographs for COVID-19 vaccines updated in Canada
724 [GO] 2021―Oct―01 Covid-19-vaccine-pfizer-biontech
725 [GO] 2021―Oct―01 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
726 [GO] 2021―Sep―24 COVID-19 vaccination safe during pregnancy
727 [GO] 2021―Sep―24 Covid-19-vaccine-pfizer-biontech
728 [GO] 2021―Sep―17 Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination
729 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech
730 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium
731 [GO] 2021―Sep―17 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
732 [GO] 2021―Sep―12 Warnings of risks associated with ivermectin use for COVID-19
733 [GO] 2021―Sep―12 mRNA-based vs viral vector-based COVID-19 vaccines
734 [GO] 2021―Sep―12 Covid-19-vaccine-pfizer-biontech
735 [GO] 2021―Sep―12 COVID-19-Vaccine-Pfizer-BioNTech
736 [GO] 2021―Sep―12 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
737 [GO] 2021―Sep―12 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
738 [GO] 2021―Sep―04 Antihypertensives: sex differences in risk of COVID-19
739 [GO] 2021―Sep―04 Thrombocytopenia and thromboembolism after COVID-19 vaccination
740 [GO] 2021―Sep―04 COVID-19 Vaccine Pfizer BioNTech
741 [GO] 2021―Sep―04 AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
742 [GO] 2021―Sep―04 Covid-19-vaccine-Pfizer-BioNTech
743 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
744 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
745 [GO] 2021―Sep―04 Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab
746 [GO] 2021―Aug―27 Covid-19 vaccine pfizer biontech
747 [GO] 2021―Aug―27 Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents
748 [GO] 2021―Aug―27 Janssen COVID-19 vaccine-related tinnitus and dizziness
749 [GO] 2021―Aug―27 Covid-19-vaccine-Pfizer-BioNTech
750 [GO] 2021―Aug―21 COVID-19 vaccination encouraged by the EMA/ECDC
751 [GO] 2021―Aug―21 Pfizer-BioNTech COVID-19 vaccine label update on Bell's palsy in Canada
752 [GO] 2021―Aug―21 Cerebral vein thrombosis after four COVID-19 vaccines in Europe
753 [GO] 2021―Aug―21 Covid-19-vaccine-pfizer-biontech
754 [GO] 2021―Aug―21 Covid-19-vaccine-Pfizer-BioNTech/prednisone
755 [GO] 2021―Aug―21 Remdesivir vs tocilizumab in COVID-19: adverse event profiles
756 [GO] 2021―Aug―13 NSAIDs do not increase risk or severity of COVID-19 infections
757 [GO] 2021―Aug―13 Cerebral venous sinus thrombosis after COVID-19 vaccination
758 [GO] 2021―Aug―13 Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
759 [GO] 2021―Aug―13 PRAC meeting 5 August 2021: COVID-19 vaccine safety issues
760 [GO] 2021―Aug―13 COVID-19-Vaccine-Pfizer-BioNTech
761 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech
762 [GO] 2021―Aug―13 Covid-19-Vaccine-Pfizer-Biontech
763 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech/levofloxacin
764 [GO] 2021―Aug―09 WHO GACVS reviews cases of GBS after COVID-19 vaccination
765 [GO] 2021―Aug―09 Rolling review of COVID-19 vaccine Vidprevtyn by EMA
766 [GO] 2021―Aug―09 Revisions of precautions for COVID-19 vaccines and other drugs in Japan
767 [GO] 2021―Aug―09 COVID-19-Vaccine-Pfizer-BioNTech
768 [GO] 2021―Aug―09 Covid-19-vaccine-pfizer-biontech
769 [GO] 2021―Aug―01 EMA assessing safety of anakinra in adults with COVID-19
770 [GO] 2021―Aug―01 PMDA: precautions should be revised for Covid-19 vaccine
771 [GO] 2021―Jul―23 Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome
772 [GO] 2021―Jul―23 PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines
773 [GO] 2021―Jul―23 COVID-19-Vaccine-Pfizer-BioNTech
774 [GO] 2021―Jul―23 Covid-19-vaccine-pfizer-biontech
775 [GO] 2021―Jul―17 AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
776 [GO] 2021―Jul―05 Myocarditis or pericarditis following COVID-19 vaccination
777 [GO] 2021―Jul―05 Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
778 [GO] 2021―Jul―05 COVID-19-vaccine-pfizer-biontech
779 [GO] 2021―Jul―05 Covid-19-vaccines
780 [GO] 2021―Jun―26 FDA reports recall of Innova COVID-19 antigen rapid qualitative test
781 [GO] 2021―Jun―26 Myocarditis and pericarditis after COVID-19 vaccination
782 [GO] 2021―Jun―26 PRAC June 2021 meeting highlights: COVID-19 vaccine AEs
783 [GO] 2021―Jun―26 US-labelled supply of Moderna's COVID-19 vaccine in Cananda
784 [GO] 2021―Jun―18 Biological or targeted synthetic DMARDs increase COVID-19 severity
785 [GO] 2021―Jun―18 Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents
786 [GO] 2021―Jun―18 Safeguarding against use of contaminated COVID-19 Vaccine Janssen
787 [GO] 2021―Jun―18 Heterogeneity in potential COVID-19 vaccine-related AEs
788 [GO] 2021―Jun―18 EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia
789 [GO] 2021―Jun―12 Nursing home resident deaths after Pfizer-BioNTech's COVID-19 vaccine
790 [GO] 2021―Jun―12 Many Danes with fever after COVID-19 vaccine would contact doctor
791 [GO] 2021―Jun―05 Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines
792 [GO] 2021―Jun―05 Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
793 [GO] 2021―Jun―05 COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab
794 [GO] 2021―May―28 Bleeding and clotting with AstraZeneca's COVID-19 vaccine
795 [GO] 2021―May―28 Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca
796 [GO] 2021―May―21 COVID-19 vaccination during pregnancy: no increase in placental lesions
797 [GO] 2021―May―21 PRAC May 2021 meeting highlights: COVID-19 vaccine AEs
798 [GO] 2021―May―21 Do NSAIDs increase the severity of COVID-19?
799 [GO] 2021―May―14 COVID-19 vaccination errors in USA reported to ISMP
800 [GO] 2021―May―14 TTS with Janssen's COVID-19 vaccine
801 [GO] 2021―May―14 Anxiety disorders with Janssen's COVID-19 vaccine
802 [GO] 2021―May―14 AstraZeneca COVID-19 vaccine-related thromboembolism
803 [GO] 2021―May―14 AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
804 [GO] 2021―May―07 No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
805 [GO] 2021―May―07 FDA and CDC recommend resuming use of Janssen COVID-19 vaccine
806 [GO] 2021―May―07 COVID-19 vaccine adverse events reported via app
807 [GO] 2021―May―07 AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
808 [GO] 2021―May―07 New EMA/ECDC initiative for monitoring COVID-19 vaccines
809 [GO] 2021―May―03 PRAC: blood clots with Janssen's COVID-19 vaccine
810 [GO] 2021―May―03 Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
811 [GO] 2021―Apr―23 FDA remote evaluation of drug manufacturing during COVID-19
812 [GO] 2021―Apr―23 Health Canada: blood clots with AstraZeneca's COVID-19 vaccine
813 [GO] 2021―Apr―23 Denmark ceases roll out of AstraZeneca's COVID-19 vaccine
814 [GO] 2021―Apr―23 COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets
815 [GO] 2021―Apr―23 PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines
816 [GO] 2021―Apr―23 Health Canada: AKI or ARF with remdesivir for COVID-19?
817 [GO] 2021―Apr―16 Should cancer patients receiving ICIs received COVID-19 vaccination?
818 [GO] 2021―Apr―16 Pfizer-BioNTech COVID-19 vaccine: AEs after vaccination in New Zealand
819 [GO] 2021―Apr―16 AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
820 [GO] 2021―Apr―10 Falsified COVID-19 vaccine recently identified in Mexico
821 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
822 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: no increased rate of VTE
823 [GO] 2021―Apr―02 No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
824 [GO] 2021―Apr―02 Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots
825 [GO] 2021―Apr―02 AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada
826 [GO] 2021―Mar―26 Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
827 [GO] 2021―Mar―26 Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
828 [GO] 2021―Mar―26 Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
829 [GO] 2021―Mar―26 March 2021 PRAC meeting highlights include COVID-19 vaccine update
830 [GO] 2021―Mar―26 COVID-19-vaccine-Pfizer-BioNTech
831 [GO] 2021―Mar―19 COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
832 [GO] 2021―Mar―19 Reports of flu-like symptoms after COVID-19 vaccination
833 [GO] 2021―Mar―19 EMA assessing cases of blood clots after AstraZeneca COVID-19 vaccine
834 [GO] 2021―Mar―19 COVID-19 vaccine AE reports in Australia and New Zealand
835 [GO] 2021―Mar―13 Vial and carton labelling updated for Moderna COVID-19 vaccine
836 [GO] 2021―Mar―13 COVID-19 vaccine-related lymphadenopathy may affect breast screening
837 [GO] 2021―Feb―26 COVID-19 vaccine safety monitoring
838 [GO] 2021―Feb―19 Second HPRA safety update on COVID-19 vaccines
839 [GO] 2021―Feb―12 MHRA Yellow Card reports on COVID-19 vaccine adverse reactions
840 [GO] 2021―Feb―12 Safety update on COVID-19 vaccine Comirnaty finds no new concerns
841 [GO] 2021―Feb―05 Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
842 [GO] 2021―Feb―05 WHO considers Pfizer BioNTech COVID-19 vaccine safe in elderly
843 [GO] 2021―Feb―05 HPRA safety update on BioNTech and Moderna COVID-19 vaccines
844 [GO] 2021―Jan―29 Norway advised to assess the very frail prior to COVID-19 vaccination
845 [GO] 2021―Jan―29 Moderna COVID-19 vaccine: 2.5 cases of anaphylaxis per million doses
846 [GO] 2021―Jan―29 ISMP reports: errors or hazards with COVID-19 vaccines
847 [GO] 2021―Jan―29 NSAID use does not increase risk of COVID-19-related death
848 [GO] 2021―Jan―22 Deaths in frail patients after Pfizer/BioNTech COVID-19 vaccination
849 [GO] 2021―Jan―22 Advice on COVID-19 vaccines approved in UK by MHRA
850 [GO] 2021―Jan―22 Safety of COVID-19 vaccines: who should see an allergist
851 [GO] 2021―Jan―21 Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
852 [GO] 2021―Jan―08 Pfizer COVID-19-related drug use and safety surveillance
853 [GO] 2021―Jan―06 Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine
854 [GO] 2020―Dec―21 COVID-19-related deaths not increased with ACE inhibitor or ARB use
855 [GO] 2020―Dec―11 EMA and ICMRA urge continuation of COVID-19 vaccine safety trials
856 [GO] 2020―Nov―27 EMA's safety monitoring plan for COVID-19 vaccines
857 [GO] 2020―Nov―20 Drug-drug interactions in patients with COVID-19
858 [GO] 2020―Nov―13 EMA guidance on risk management plans for COVID-19 vaccines reviewed
859 [GO] 2020―Nov―06 Quality of ADR reporting evaluated for remdesivir trials of COVID-19
860 [GO] 2020―Nov―06 Hydroxychloroquine-related psychiatric disorders in COVID-19 patients
861 [GO] 2020―Nov―06 Phase III trial of Covid-19 treatment paused for safety concerns
862 [GO] 2020―Nov―06 Concerns raised with MHRA of anticoagulant use during pandemic
863 [GO] 2020―Oct―16 Remdesivir-related acute kidney injury in patients with COVID-19
864 [GO] 2020―Oct―02 Sex differences in ADR reports for drugs used to treat COVID-19
865 [GO] 2020―Aug―14 Proton pump inhibitors increase risk of COVID-19
866 [GO] 2020―Aug―14 Health Canada approves first drug for treatment of COVID-19
867 [GO] 2020―Jul―24 Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
868 [GO] 2020―Jul―17 Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
869 [GO] 2020―Jun―26 New potential interaction with emergency COVID-19 medicine remdesivir
870 [GO] 2020―Jun―12 Benefit-risk assessment for remdesivir in COVID-19
871 [GO] 2020―Jun―12 Risks of chloroquine or hydroxychloroquine use for COVID-19
872 [GO] 2020―Jun―05 COVID-19 pregnancy prevention guidance on teratogenic drugs
873 [GO] 2020―Jun―05 UK's MHRA publishes guidance for valproate PPP during pandemic
874 [GO] 2020―May―29 Chloroquine and hydroxychloroquine increase risk of death in COVID-19
875 [GO] 2020―May―29 Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
876 [GO] 2020―May―29 Cardiac adverse reactions with off-label Covid-19 treatments
877 [GO] 2020―May―23 US guidance issued for postmarketing AE reporting during pandemic
878 [GO] 2020―May―18 International Society of Pharmacovigilance: COVID-19 role
879 [GO] 2020―May―18 MHRA COVID-19 website for reporting ADRs and incidents
880 [GO] 2020―May―18 Risk of Covid-19 with renin-angiotensin-aldosterone system medications
881 [GO] 2020―May―11 Evaluation of potential therapies for COVID-19 global pandemic
882 [GO] 2020―May―11 Demand for potentially hazardous COVID-19 treatments
883 [GO] 2020―May―11 UMC: use appropriate COVID-19-related terms for ICSRs
884 [GO] 2020―May―04 ACEI inhibitors and ARBs do not increase severity of COVID-19
885 [GO] 2020―May―04 Safety concerns with higher dosage chloroquine in COVID-19 patients
886 [GO] 2020―May―04 High incidence of ADRs in COVID-19 patients in China
887 [GO] 2020―May―04 Antimalarial use in COVID-19 patients requires close monitoring
888 [GO] 2020―Apr―20 EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic
889 [GO] 2020―Apr―06 Regulatory agencies issue advice on use of NSAIDs for COVID-19

889 Results       Page 1


Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.062 sec